Uterine Fibroid Treatment Market Is Driven by Rising Healthcare Expenses

The uterine fibroid treatment market was USD 3,121.1 million in 2022, which will touch USD 6,714.4 million, advancing at a 10.1% compound annual growth rate, by 2030.

The progression of this industry is because of the increasing count of patients with uterine fibroids, the rising incidence of hormonal conditions in females, and the mounting female elderly population.

In 2022, the intramural fibroids category, on the basis of type, was the largest contributor to the industry, with a share of 60%. This can be because of the rising incidence of intramural fibroids among female populations across the globe.

North America led the industry, with a 40% share, in 2022. This is because of the reputable healthcare sector in Canada and the U.S., the easy availability of novel technologies, and the surging occurrence of uterine fibroids in this region.

In addition, the growth of the regional industry is also driven by the growing number of patients with hormonal disorders as well as uterine cancers in this continent.

Get free sample copy of this report: https://www.psmarketresearch.com/market-analysis/uterine-fibroid-treatment-market/report-sample

APAC is likely to propel at the highest compound annual growth rate, of approximately 12%. This will be because of the rising widespread incidence of irregular uterine bleeding, irregular menstrual cycles among women, and increasing healthcare expenditures.

Moreover, the rising per capita income resulting in better living standards, increasing need for better healthcare, and growing consciousness regarding uterine fibroid treatment are also boosting the regional industry.

With the rising healthcare spending and mounting female elderly populace, the uterine fibroid treatment industry will continue to progress in the coming years.